Post-Marketing Surveillance of the Safety of Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhythmias
The safety profile of landiolol in this PMS was similar to that observed in a prior clinical trial, and no new safety signals were identified. Landiolol is an option for treating refractory and potentially fatal VF or hemodynamically unstable VT.
Authors
- Ryōji Matsumoto (ORCID: https://orcid.org/0000-0002-9500-384X)
- Maki Shiozaki
- Tsuyoshi Shiga (ORCID: https://orcid.org/0000-0003-0358-7196)
- Rika Takahashi
- Masato Fukui
Institutions
- Jikei University School of Medicine (JP)
Publication Details
- Journal
- Circulation Journal
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1253/circj.cj-24-0898
- Citations
- 3
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- Ono Pharmaceutical